Thursday, February 15, 2018 1:22:08 PM
http://www.princetonresearch.com/featured-investments/
Mike King
702 650 3000
Princeton Research
or
King Mike
mike@princetonresearch.com
(702) 493-3683
In alot of ways repr fills your criteria. The company is debt free and is funding future growth internally. This means its unlikely to have dilute secondary offerings. I do not see any negative surprises. The FDA thing has come and gone. I believe this was a blessing in disguise. It forced the company to upgrade its quality assurance procedures to the highest level. This can only help them marketing their products. The real sizzle lies in the potential propriety pump technology being used with other drugs. This could result in an avalanche of new orders and growth. Additionally the suction device res-q-vac, might eventually get into the military. This has been dangled in from of the stock holders for years. Who knows?
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM